Jeff Liter
YOU?
Author Swipe
View article: Phase 1 assessment of novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)
Phase 1 assessment of novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) Open
Background and Significance: Marked success has been achieved using scFv-based CAR-T cell therapies targeting CD19 and BCMA to treat lymphoma and myeloma. Response rates are high, but a significant number of patients fail to respond or rel…
View article: PRCA-04 TARGETING A UNIQUE ACTIVATION RECEPTOR COMPLEX TO TREAT INTRACRANIAL BREAST CARCINOMA.
PRCA-04 TARGETING A UNIQUE ACTIVATION RECEPTOR COMPLEX TO TREAT INTRACRANIAL BREAST CARCINOMA. Open
Despite enhanced therapies against primary breast carcinoma (BC), intracranial metastases remain incurable and are associated with a decreased quality of life. To address this unmet medical need, we developed a new therapy (ARL200CNS), rep…